Methotrexate has become the agent of choice for rheumatoid arthritis that does not respond to nonsteroidal anti-inflammatory drugs. In appropriately selected patients and with diligent monitoring, methotrexate in low weekly doses is effective and has a much better safety profile than was originally perceived.
|Original language||English (US)|
|Number of pages||9|
|Journal||Cleveland Clinic journal of medicine|
|State||Published - Jan 1 1995|
ASJC Scopus subject areas